Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With Coronary Artery Disease . The NOVELTY Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Hellenic Cardiovascular Research Society
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Hellenic Cardiovascular Research Society
ClinicalTrials.gov Identifier:
NCT02071212
First received: February 21, 2014
Last updated: August 26, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to investigate the potential acute and chronic effect of ticagrelor versus clopidogrel on arterial stiffness and other vascular risk markers of interest, the study will consist of two periods: a 24-hour ACUTE period where 60 subjects with an indication for coronary angiography (CA) with or without percutaneous coronary intervention (PCI) will be included, and a 30-day CHRONIC period where approximately 60 subjects that will undergo PCI will be included and studied (refer to Section 3 'Study Plan and Procedures'). The primary objective of this study is to compare ticagrelor versus clopidogrel regarding their effect on arterial stiffness as assessed by PWV, at 3 hours after the loading dose of each regimen, in eligible subjects with CAD.


Condition Intervention Phase
Coronary Artery Disease
Drug: Ticagrelor
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Single Center Phase II Assessor -Blinded RaNdomised Active Controlled Parallel-Group Trial to COmpare Ticagrelor Versus Clopidogrel on the REduction of ArteriaL STiffness and Wave Reflections in Patients With CoronarY Artery Disease. The NOVELTY Study

Resource links provided by NLM:


Further study details as provided by Hellenic Cardiovascular Research Society:

Primary Outcome Measures:
  • Mean Change in the cfPWV [ Time Frame: at 3 hours after the loading dose ] [ Designated as safety issue: No ]
    The primary outcome is the treatment difference in the mean change in cfPWV from baseline (0 hours) at 3 hours after the loading dose of each regimen, in ticagrelor and clopidogrel acute period populations.


Secondary Outcome Measures:
  • mean change in the cfPWV [ Time Frame: from baseline at 24 hours after the loading dose ] [ Designated as safety issue: No ]
    The treatment difference in the mean change in the cfPWV from baseline (0 hours) at 24 hours after the loading dose of each regimen, in the acute period populations;


Estimated Enrollment: 120
Study Start Date: February 2014
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Clopidogrel
Loading dose 600 mg .Mainatinance dose 75 mg QD
Drug: Ticagrelor
Loading dose 180 mg . Maintainance dose 90 mg BID
Other Name: BRILIQUE
Experimental: Ticagrelor
Loading dose 180 mg . Maintenance 90 mg BID
Drug: Ticagrelor
Loading dose 180 mg . Maintainance dose 90 mg BID
Other Name: BRILIQUE

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures.
  2. Male and female subjects > 18 and < 79 years of age.
  3. Indication for elective coronary angiography (angina, positive stress test/SPECT/stress echo) with or without PCI for inclusion in the 'acute' study period, and indication for either ad hoc or elective PCI for inclusion in the 'chronic' study period.

Exclusion Criteria:

  1. Who had ACS within 12 months of screening.
  2. Previous stent implantation with dual antiplatelet therapy within 12 months of screening.
  3. Subjects being treated with anti-platelet medications other than aspirin prior to diagnostic catheterization including glycoprotein IIb/IIIa inhibitors.
  4. Subjects with NYHA class III or IV heart failure or known left ventricular ejection fraction < 30%.
  5. Subjects with hemodynamic or electrical instability (including shock).
  6. History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.
  7. Other bleeding diathesis, or considered by Investigator to be at high risk for bleeding.
  8. Any previous history of ischemic or hemorrhagic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
  9. International Normalized Ratio (INR) known to be >1.5 within 1 week of study entry.
  10. Poorly controlled blood pressure (>160/100 mmHg).
  11. Known platelet count of <100,000/mm3 within 1 week of study entry.
  12. Known anemia (hemoglobin [Hb] <10 gr/dL) within 1 week of study entry.
  13. Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
  14. Severe kidney disease (GFR<30 ml/min/1.73m2).
  15. Hepatic insufficiency defined as liver cirrhosis, AST/ALT/Alkaline Phosphatase greater than 3 times the upper limit of normal or hyperbilirubinemia defined as peak total serum bilirubin greater than 2 times the upper limit of normal (ULN).
  16. Any indication (atrial fibrillation, mitral stenosis or prosthetic heart valve, pulmonary embolism (PE), deep vein thrombosis (DVT)) for anticoagulation treatment during study period.
  17. Asthma or chronic obstructive pulmonary disease requiring brochodilating agents.
  18. Concomitant use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine).
  19. Concomitant use of drugs that are metabolized through CYP2C19 (omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol).
  20. History of uric acid nephropathy and high levels of uric acid within 1 week of study entry.
  21. Increased risk of bradycardic events (e.g. known sick sinus syndrome or third degree AV block or previous documented syncope suspected to be due to bradycardia unless treated with a pacemaker).
  22. Known neoplastic or autoimmune disease or any concomitant medical illness that in the opinion of the Investigator may interfere with or prevent completion in this study.
  23. Contraindication to clopidogrel, ASA, or ticagrelor.
  24. A history of alcohol and/or substance abuse that could interfere with conduct of the trial.
  25. Pregnancy or lactation (for premenopausal women 2 methods of reliable contraception, one of which must be barrier method, are required).
  26. Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the Day 30 visit.
  27. Life expectancy less than 1 year.
  28. Indication for major surgery (e.g. cancer treatment, carotid surgery, cerebral surgery, major vascular surgery).
  29. High likelihood of being unavailable for the Day 30 follow up.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02071212

Contacts
Contact: Charalambos Vlachopoulos, Associate Prof cvlachop@otenet.gr

Locations
Greece
Ippokratio Hospital Recruiting
Athens, Greece
Principal Investigator: Charalambos Vlachopoulos, Associate Professor         
Sponsors and Collaborators
Hellenic Cardiovascular Research Society
AstraZeneca
Investigators
Principal Investigator: Charalambos Vlachopoulos Ippokratio Hospital Athens , Greece
  More Information

No publications provided

Responsible Party: Hellenic Cardiovascular Research Society
ClinicalTrials.gov Identifier: NCT02071212     History of Changes
Other Study ID Numbers: D5130L00063
Study First Received: February 21, 2014
Last Updated: August 26, 2014
Health Authority: Greece: Ministry of Health and Welfare

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Clopidogrel
Ticagrelor
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 18, 2014